| Description | Troriluzole is an orally active glutamate modulator with anticancer activity.Troriluzole enhances the expression of excitatory amino acid transporters located in glial cells and is used in the study of spinocerebellar ataxia, Alzheimer's disease, and generalized anxiety disorder (GAD). |
| In vitro | Troriluzole 是 EAAT2 调节剂、NMDA receptor 拮抗剂以及 Nav1.5 阻滞剂，常用于强迫症等神经系统疾病研究[1]。 |
| Synonyms | BHV4157, BHV-4157, BHV-4157a, FC 4157, BHV 4157 |
| molecular weight | 419.38 |
| Molecular formula | C15H16F3N5O4S |
| CAS | 1926203-09-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 30 mg/mL (71.53 mM), Sonication is recommended. |
| References | 1. Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov;28(11):1003-1012. 2. Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27(1):18. |